Genomic sequencing to inform therapy in advanced pancreatic cancer : A systematic review and meta-analysis of prospective studies
Copyright © 2021 Elsevier Ltd. All rights reserved..
PURPOSE: Current guidelines recommend somatic genomic sequencing for patients with advanced pancreatic cancer to identify targetable alterations amenable to targeted therapy. The benefit of somatic genomic sequencing in pancreatic cancer remains unclear. This study aims to assess the evidence supporting genomic sequencing to inform treatment selection for patients with advanced pancreatic cancer.
METHODS: A systematic review identified prospective studies of exocrine pancreatic cancer patients published before August 2020 which conducted genomic sequencing to inform treatment selection. Outcomes of interest included the proportion of patients with targetable alterations, the proportion that received targeted treatments, and the impact of targeted treatments on overall survival. Meta-analysis for proportions and hazard ratios was performed using Dersimonian and Laird random effect models.
RESULTS: 19 studies (representing 2048 pancreatic cancer patients) were included. Sequencing methodologies, definitions of targetable alterations, and approaches treatment selection varied across studies and were incompletely reported. 590 of 1382 sequenced patients harboured a targetable alteration (random effects meta-analysis estimate of the proportion 0.46, 95% confidence interval 0.32-0.61). The proportion of patients with targetable alterations was highly heterogenous between studies (I2 93%, P < 0.001). 91 of 1390 patients received a matched therapy based on their targetable alterations (random effects meta-analysis estimate of the proportion 0.12, 95% CI 0.06-0.23). One observational study reported an overall survival benefit of matched therapy.
CONCLUSIONS: Genomic sequencing frequently identifies targetable alterations in pancreatic cancers. Further research is required to standardize the definitions of targetable alterations, the approach to treatment matching, and quantify the benefit of targeted therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Cancer treatment reviews - 101(2021) vom: 15. Dez., Seite 102310 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meti, Nicholas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genomics |
|---|
| Anmerkungen: |
Date Completed 22.11.2021 Date Revised 22.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ctrv.2021.102310 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332952479 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332952479 | ||
| 003 | DE-627 | ||
| 005 | 20231225220632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2021.102310 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332952479 | ||
| 035 | |a (NLM)34757307 | ||
| 035 | |a (PII)S0305-7372(21)00158-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meti, Nicholas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genomic sequencing to inform therapy in advanced pancreatic cancer |b A systematic review and meta-analysis of prospective studies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2021 | ||
| 500 | |a Date Revised 22.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a PURPOSE: Current guidelines recommend somatic genomic sequencing for patients with advanced pancreatic cancer to identify targetable alterations amenable to targeted therapy. The benefit of somatic genomic sequencing in pancreatic cancer remains unclear. This study aims to assess the evidence supporting genomic sequencing to inform treatment selection for patients with advanced pancreatic cancer | ||
| 520 | |a METHODS: A systematic review identified prospective studies of exocrine pancreatic cancer patients published before August 2020 which conducted genomic sequencing to inform treatment selection. Outcomes of interest included the proportion of patients with targetable alterations, the proportion that received targeted treatments, and the impact of targeted treatments on overall survival. Meta-analysis for proportions and hazard ratios was performed using Dersimonian and Laird random effect models | ||
| 520 | |a RESULTS: 19 studies (representing 2048 pancreatic cancer patients) were included. Sequencing methodologies, definitions of targetable alterations, and approaches treatment selection varied across studies and were incompletely reported. 590 of 1382 sequenced patients harboured a targetable alteration (random effects meta-analysis estimate of the proportion 0.46, 95% confidence interval 0.32-0.61). The proportion of patients with targetable alterations was highly heterogenous between studies (I2 93%, P < 0.001). 91 of 1390 patients received a matched therapy based on their targetable alterations (random effects meta-analysis estimate of the proportion 0.12, 95% CI 0.06-0.23). One observational study reported an overall survival benefit of matched therapy | ||
| 520 | |a CONCLUSIONS: Genomic sequencing frequently identifies targetable alterations in pancreatic cancers. Further research is required to standardize the definitions of targetable alterations, the approach to treatment matching, and quantify the benefit of targeted therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Genomics | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Pancreatic cancer | |
| 650 | 4 | |a Profiling | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Kelly, Deirdre |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Lanys, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Fazelzad, Rouhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ramjeesingh, Ravi |e verfasserin |4 aut | |
| 700 | 1 | |a Zogopoulos, George |e verfasserin |4 aut | |
| 700 | 1 | |a Notta, Faiyaz |e verfasserin |4 aut | |
| 700 | 1 | |a Knox, Jennifer J |e verfasserin |4 aut | |
| 700 | 1 | |a Amir, Eitan |e verfasserin |4 aut | |
| 700 | 1 | |a Gallinger, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a O'Kane, Grainne |e verfasserin |4 aut | |
| 700 | 1 | |a Grant, Robert C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer treatment reviews |d 1993 |g 101(2021) vom: 15. Dez., Seite 102310 |w (DE-627)NLM000409189 |x 1532-1967 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2021 |g day:15 |g month:12 |g pages:102310 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctrv.2021.102310 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2021 |b 15 |c 12 |h 102310 | ||